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The effects of lubricant eye drops on visual 
function as measured by the inter-blink interval 
Visual Acuity Decay test
gail Torkildsen
Andover eye Associates, Andover, 
MA, UsA
Objective: The purpose of the current study was to evaluate the effects of two marketed ocular 
lubricants on the visual decay in dry eye patients using the Inter-blink interval Visual Acuity 
Decay (IVAD) test.
Methods: This controlled, randomized, double-masked crossover study compared the effects 
of a polyethylene glycol/propylene glycol-based (PEG/PG) tear and a carboxymethylcellulose 
sodium (CMC)/glycerin tear on the visual acuity decay between blinks of dry eye patients. 
At visit 1 (Day 0), baseline IVAD measurements were recorded prior to instillation of a single 
drop of randomized study medication. IVAD testing was repeated at 15-, 45-, and 90-minutes 
post-instillation. Reading rate and functional blink rate were also evaluated. At the second visit 
(Day 7 ± 3), study procedures were repeated using crossover treatment.
Results: Forty-eight (48) subjects with dry eye (61.1 ± 14.8 years old, 79.2% female, 
95.8% white) completed the study. Treatment with the PEG/PG-based tear demonstrated 
statistically significantly longer time to one-line loss of best-corrected visual acuity (BCVA) 
as determined by the IVAD test at 90 minutes post-instillation compared to the CMC/glycerin 
tear (P = 0.0365). Measurements of median time at BCVA, reading rate, and functional blink 
rate were similar for both treatments. Both formulations were well tolerated in the population 
studied.
Conclusions: Treatment with the PEG/PG-based tear demonstrated statistically significant 
improved maintenance of visual acuity between blinks at 90 minutes post-instillation compared 
to the CMC/glycerin tear. This is the first study to demonstrate the ability of an artificial tear to 
extend visual acuity maintenance between blinks, as measured by the IVAD test.
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Introduction
The objective signs and subjective symptoms of dry eye fluctuate greatly across patient 
populations, creating a significant challenge for the clinician to diagnose and treat the 
condition effectively. A more recent area of study in dry eye is the implications for 
visual function. The decreased blink rate experienced during visual function tasks, 
(eg, extended computer use, reading, video gaming, watching TV) can exacerbate 
dry eye and the signs and symptoms of dry eye (eg, blurred vision, ocular surface 
staining, short tear film break-up time [TFBUT]), which, in turn, can limit patients’ 
visual functioning capabilities. Not surprisingly, this reciprocal relationship between 
dry eye and visual tasking can confound the clinician’s diagnosis and treatment even 
further. Patient complaints of the effect of dry eye on visual function may include 
difficulty driving, reading, and watching television.1
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During each blink of the eye, the action of the upper lid 
serves the essential purpose of reestablishing the tear film 
over the ocular surface epithelium.2 The tear film instability 
and increased rates of tear film break-up following a blink that 
are characteristic of dry eye can be caused by insufficiencies 
in any of the three major tear film components: lipid, mucin, 
and aqueous.3,4 Ocular surface protection is contingent upon 
the patient’s TFBUT matching or exceeding his or her inter-
blink interval (IBI).5 Blink rate is thereby closely integrated 
with ocular surface integrity.
The effects of dry eye on visual function can be assessed 
by testing the visual acuity degradation during the IBI. The 
Inter-blink Interval Visual Acuity Decay (IVAD) test is a 
novel diagnostic tool that evaluates functional visual acuity 
between blinks. It is a computer-based visual task which 
involves identification of Landolt ‘c’s at individualized best-
corrected visual acuity (BCVA) between blinks and measures 
parameters based on patient responses. During the test, the 
rotating optotype ‘c’ is presented and the subject responds 
using a keypad to indicate the direction of the ‘c’.1 By using 
a standardized task for all patients before and after treatment, 
the test is designed to establish an accurate representation of 
the effects of dry eye treatments on visual function.
A new artificial tear, Systane® Ultra Lubricant Eye Drops 
(Alcon, Inc., Fort Worth, TX, USA), contains polyethylene 
glycol 400 (PEG 400) and propylene glycol (PG) as active 
demulcents, gelling agent HP-Guar, sorbitol, and preserva-
tive POLYQUAD. The viscosity is optimized in the bottle 
with sorbitol to allow for efficient ocular spreading with 
minimal blur. Upon instillation, the solution then interacts 
with the mucins and divalent ions of the natural tear film 
and releases sorbitol, allowing enhanced cross-linking of 
borate with HP-Guar, and forming a matrix on the ocular 
surface.6 Optive™ (Allergan, Inc., Irvine, CA, USA) contains 
carboxymethylcellulose sodium (CMC) and glycerin, and is 
preserved with Purite.7 The drops were chosen as compara-
tors because they contain different polymeric formulations 
and target similar dry eye populations.
Over-the-counter (OTC) artificial tears are the mainstay 
in dry eye treatment, and impact the visual function capa-
bilities of patients. Clinical studies of artificial tears have 
demonstrated differences in blurring effects upon instillation 
between marketed products, as well as the relationship of 
residence time to this blurring upon-instillation.8,9 Knowledge 
of the considerable impact of dry eye on visual function and 
the implications for quality-of-life led to further investiga-
tion of the effects of dry eye treatment on visual function. 
The present study was designed to evaluate the effect of two 
lubricant eye drops (Systane Ultra and Optive) on visual 
function of dry eye patients using the IVAD test.
Methods
This study utilized a single-center, randomized, double 
masked, cross-over design to evaluate the visual function 
effects of two lubricant eye drops in patients with dry eye. 
The study protocol, protocol amendments, informed consent 
form, investigator qualifications and site, and recruiting 
materials were approved by an Institutional Review Board 
(Southwest Independent; Fort Worth, TX). The study was 
conducted in accordance with current Good Clinical Practice 
guidelines and the Declaration of Helsinki.
Subjects were recruited from an existing database of 
dry eye patients, and were enrolled in the study if they 
met all inclusion and no exclusion criteria. Enrolled subjects 
were at least 18 years of age, provided written informed 
consent, and had a reported history of dry eye in both eyes. 
Enrolled subjects also had a documented history within the 
previous 6 months of both a TFBUT  5 seconds and a 
sodium fluorescein corneal staining sum score of 1 (on a 
standardized 0 [none] to 4 [worst] scale)10 in both eyes. 
Subjects were enrolled if they reported a use and/or desire to 
use an artificial tear within the past year, and had a BCVA of 
0.6 logMAR or better in each eye using the Early Treatment 
of Diabetic Retinopathy Study (ETDRS) chart. Subjects 
were excluded if they had undergone ocular surgery in the 
previous 6 months, had current punctal occlusion, had a 
history of intolerance or hypersensitivity to any component 
of the study medications, or had a history or evidence of 
external ocular infection. Subjects who had a history or 
evidence of glaucoma, ocular hypertension, and intraocular 
inflammation; and those who used systemic medications 
known to cause ocular drying on an unstable dose for the 
30 days prior to visit 1 were also excluded from the study. 
Subjects who had any ocular or systemic medical condition 
that might, in the opinion of the investigator, preclude the 
safe administration of test product, were excluded as well. 
Use of topical ocular drops within 3 hours of visit 1, use of 
Restasis® (Allergan) within 30 days of visit 1, and use of 
either (except in the case of artificial tears) throughout the 
duration of the study were disallowed.
At visit 1 (day 0) subjects provided written informed 
consent and signed a Health Insurance Portability and 
Accountability Act (HIPAA) privacy document prior to any 
study procedures. Demographic information as well as medi-
cal and medication history were obtained from the subject. 
Each subject’s BCVA was tested using the ETDRS chart, Clinical Ophthalmology 2009:3 503
Lubricant eye drops effects on visual function Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
and primary gaze blink rate was obtained using a digital 
microcamera and infrared illuminator while the subject was 
isolated and asked to complete a standard visual task (subjects 
were not instructed that their blink rate was being monitored). 
Each subject’s functional blink rate was acquired during a 
practice session of the IVAD test. Reading rate was deter-
mined by timing each subject while reading a list of 16 words, 
one eye at a time. Slit lamp examination of the anterior eye 
was conducted on both eyes of the subjects.
As subjects qualified, they were assigned enrollment 
numbers in numerical sequence, and these numbers corre-
sponded to the treatment order for the two test products. 
After resting for at least 5 minutes, 1 drop of randomized 
treatment was instilled in both eyes by a designated member 
of the investigative staff who was not involved in clinical 
assessment, data management, or data analysis, and who 
did not disclose treatment assignments to the investigator, 
sponsor, or patients. Subjects then underwent functional blink 
rate assessment, IVAD testing, and reading rate evaluation 
at 15, 45, and 90 minutes post-dose. Finally, any adverse 
events reported or observed after instillation of test product 
were recorded and assessed and subjects were scheduled for 
their next visit. Subjects returned for visit 2 on day 7 ± 3, 
and were queried for artificial tear use in the 3 hours prior to 
their visit and any adverse event occurrence since visit 1, and 
the same method was applied for the cross-over treatment, 
followed by study exit.
statistical analysis
All patients receiving test product were considered evaluable 
for the safety analysis and all patients receiving test product 
and completing both visits were considered evaluable for 
the intent-to-treat (ITT) analysis. All patients who met the 
criteria for ITT analysis, and satisfied all inclusion and exclu-
sion criteria were considered evaluable for the per-protocol 
(PP) analysis.
The primary efficacy variables were IVAD test recorded 
time at BCVA and reading rate of the worse eye as assessed 
at baseline and 15, 45, and 90 minutes post-dose. Descriptive 
statistics were presented for each of the efficacy variables 
(including the mean, standard deviation, sample size, 
minimum, and maximum) and by treatment and time points. 
Repeated measures analysis of variance (ANOVA) were used 
to test for treatment differences in the IVAD test recorded 
time and reading rate of the worse eye. Descriptive statistics 
for the secondary variable of functional blink rate assessed 
at baseline and 15, 45, and 90 minutes post-treatment were 
generated by treatment and time points. Repeated measures 
of variance were used to test for treatment differences in 
functional blink rate. Post hoc exploratory efficacy analysis 
was conducted using survival analyses (right censored) per-
formed for IVAD time at BCVA at 15, 45, and 90 minutes 
post-dose. Observations were censored if time at BCVA was 
equal to IBI.
Results
Fifty-three subjects were screened and 48 subjects were 
enrolled in the study, completed all visits, and were evaluable 
for safety, ITT and PP analyses (mean age = 61.1 ± 14.8 years; 
20.8% male; 95.8% white, 2.1% black, 2.1% other). Since the 
ITT and PP data sets were identical, analyses were performed 
only on the ITT set.
The results for time at BCVA, reading rate, and functional 
blink rate measurements are listed in Table 1. A significant 
difference in survival distribution for time at BCVA (time 
to one-line loss of BCVA) evaluated using the IVAD test 
was observed at 90 minutes post-dose: 50% of patients 
demonstrated time to one-line loss of BCVA greater than 
9.17 seconds in PEG 400/PG treatment group compared to 
6.84 seconds in CMC/glycerin treatment group (Wilcoxon 
test, P = 0.037; see Table 2, Figure 1). Repeated measures 
ANOVA (used to compare treatment differences in mean 
scores by time because ANOVA allows tests for treatment-
by-time and treatment-by-sequence interactions) showed no 
significant between-treatment differences for time at BCVA 
overall (P = 0.49) or any time point (P  0.36), for reading 
rate overall (P =  0.082) or at any timepoint (P  0.20), 
or for functional blink rate overall (P = 0.1408) or at any 
timepoint (P  0.14). No adverse events related to the test 
product were reported and no patients discontinued due to 
an adverse event.
Discussion
The current study was designed to demonstrate the visual 
function impact of two lubricant eye drops through the 
use of the IVAD test. The IVAD test has been utilized in 
prior studies, demonstrating the statistically significantly 
shorter time at which dry eye patients could maintain their 
BCVAs compared to normals (P = 0.0001).1 The present 
study utilized this clinical tool in order to investigate the 
potential benefits of artificial tear use on these visual function 
parameters in dry eye patients.
Although no significant between-treatment differences 
were observed in the mean values of reading rate or func-
tional blink rate at any time point post-treatment, the survival 
distribution for time at BCVA demonstrated a statistically Clinical Ophthalmology 2009:3 504
Torkildsen Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
significant difference between treatments at 90 minutes 
post-dose favoring the PEG 400/PG formulation (Wilcoxon 
test, P = 0.0365). The ability of the PEG 400/PG formulation 
to extend the amount of time to one-line loss of BCVA for 
prolonged periods of time, as demonstrated by the IVAD test, 
may suggest beneficial visual effects for patients. The link 
between visual function loss and diminished quality-of-life 
is well established in literature.11,12 The ability of ocular 
lubricants to stabilize the tear film during visual tasking and to 
retard the visual acuity decay between blinks likely translates 
to enhanced visual functioning capabilities for patients.
Previous research has explored the residence time and 
duration of action of lubricant eye drops. A prior study 
compared the duration of tear film stability achieved by the 
CMC/glycerin tear to that of a PEG 400/PG tear (a formulation 
with similar active ingredients to that used in the present study). 
The results of the study demonstrated that the PEG 400/PG 
drop achieved significantly greater extension of TFBUT at 45, 
60, and 90 minutes post-instillation than the CMC/glycerin 
drop (P  0.05). While similar ocular surface protection was 
determined to result with both artificial tears immediately 
following instillation, the PEG 400/PG tear was able to prolong 
TFBUT and maintain positive changes in Ocular Protection 
Index up to 90 minutes post-instillation.13 These results may 
suggest the prolonged duration of action of the PEG 400/PG 
formulation used in the current study, as noted in the ability to 
positively impact the time to one-line loss of BCVA 90 minutes 
post-instillation. Additionally, previous work has shown that the 
PEG 400/PG formulation used in this study has enhanced 
rheological properties, including those resulting from the dilu-
tion of sorbitol upon introduction to the tear film, which may 
also help to explain the effect at 90 minutes.14
While this data is important, no significant differences 
from baseline in BCVA maintenance existed for either drug 
until 90 minutes post-instillation, when both tears appeared to 
show their maximum effectiveness. The ability of an artificial 
tear to promote visual function abilities has the potential to 
benefit various dry eye patient populations. In order to elabo-
rate upon the extent of these visual effects, future research 
could examine the impact of visual function improvement 
Table 2  Median time to one-line loss of BCVA as measured by the iVAD test
Time post-treatment 
(minutes)
PEG 400/PG/HP-Guar, 
mean (SD)
CMC/glycerin, 
mean (SD)
P value
Baseline 5.78 5.77 0.37
15 7.75 6.42 0.65
45 6.46 5.51 0.40
90 9.17 6.84 0.037*
Note: *Statistically significant at P  0.05.
Abbreviations: BCVA, best-corrected visual acuity; iVAD, inter-blink interval visual acuity decay; Peg, polyethylene glycol; Pg, propylene glycol; CMC, carboxymethylcellulose 
sodium.
Table 1 Efficacy variables
Time post-treatment 
(minutes)
PEG 400/PG/HP-Guar, 
mean (SD)
CMC/glycerin, 
mean (SD)
P value
IVAD time  
at BCVA (sec)
Baseline 6.6 (4.1) 6.3 (4.9) 0.78
15 7.4 (5.4) 8.4 (13.1) 0.63
45 7.4 (5.6) 9.4 (13.9) 0.36
90 8.7 (9.9) 8.3 (15.5) 0.84
Reading  
rate (sec)
Baseline 10.9 (3.6) 10.7 (3.3) 0.55
15 11.4 (4.9) 11.0 (3.0) 0.37
45 11.3 (3.8) 10.8 (3.0) 0.21
90 10.8 (3.3) 10.5 (2.5) 0.39
Functional blink  
rate (sec)
Baseline 5.7 (5.4) 6.9 (5.1) 0.04*
15 5.9 (5.5) 5.8 (4.7) 0.79
45 5.9 (5.4) 6.7 (4.9) 0.17
90 6.5 (5.8) 7.3 (6.0) 0.15
*Statistically significant at P  0.05.
Abbreviations: BCVA, best-corrected visual acuity; iVAD, inter-blink interval Visual Acuity Decay; Peg, polyethylene glycol; Pg, propylene glycol; CMC, carboxymethylcellulose sodium.Clinical Ophthalmology 2009:3 505
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Figure 1 Median time to one-line loss of best-corrected visual acuity (BCVA) as assessed by the inter-blink interval Visual Acuity Decay (iVAD) test (intent-to-treat 
population; *P  0.05, Wilcoxon test).
Abbreviations: CMC, carboxymethylcellulose sodium; Peg, polyethylene glycol; Pg, propylene glycol.
on patient quality-of-life over longer-term artificial tear use; 
the potential correlation of sign and symptom reduction with 
visual function improvement; or the use of artificial tears while 
performing specific visual function tasks (eg, driving at night, 
computer use, watching television). Investigating the potential 
effects of artificial tear use on visual function in patients who 
may not be diagnosed with dry eye, but who may experience 
ocular discomfort when acutely exacerbated by prolonged 
periods of visual tasking, could illuminate potential benefits 
of ocular lubricants in that population as well.
Conclusion
Both formulations were generally well tolerated in the 
population studied. No significant between-treatment differ-
ences were observed in mean scores for reading rate at any 
of the time points measured post-treatment. Median time to 
one-line loss of BCVA as measured using the more sensitive 
measure of the IVAD test, however, was significantly longer 
with the PEG 400/PG ocular lubricant than the CMC/glycerin 
product 90 minutes post-instillation. This is the first clinical 
trial using the novel IVAD test to demonstrate the ability 
of lubricant eye drops to extend visual acuity maintenance 
between blinks.
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